BCHE and Alzheimer disease: That clinical Lewy body disease was more indicative of dual AD+LBD pathology may support the utility of cholinesterase inhibitors and memantine in this population (Wang et al., 2015), and also suggests that such patients may be candidates for amyloid-lowering therapies, which could be addressed in future clinical trials.